Journal Article DKFZ-2026-01706

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
The European Association for Neuro-oncology (EANO) Consensus Statement on Radiation Necrosis.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2026
Oxford Univ. Press Oxford

Neuro-Oncology nn, nn () [10.1093/neuonc/noag153]
 GO

Abstract: Radiation necrosis (RN) complicates neuro-oncological care, mimicking tumor recurrence and lacking high-level evidence for standardized management.A European Association for Neuro-Oncology (EANO) expert panel utilized a three-round Delphi process to create a comprehensive expert opinion document based on the available current scientific evidence. A series of statements, derived from the published literature were created by the experts in each field. Consensus was defined as ≥ 80% agreement using a 5-point Likert scale.After three rounds among 20 experts that included adaptation of statements, the Delphi process reached a consensus (≥80% agreement) on 53 statements out of 57. RN occurs in 4% to 30% of patients, typically appearing 6 to 24 months after radiotherapy for primary (glial) or metastatic brain tumors. Experts identified perfusion MRI and amino acid PET as the most suitable imaging modalities for differentiation from tumor recurrence. While histopathology remains the gold standard, identifying viable tumor cells in irradiated gliomas is challenging due to overlapping cytological features with reactive glia. For symptomatic management, corticosteroids may be tried, and bevacizumab is recommended for corticosteroid-refractory cases, with evidence suggesting profound efficacy even at low doses. Surgery is considered effective for rapid symptom relief and definitive diagnosis in accessible lesions. Laser Interstitial Thermal Therapy (LITT) can be considered an additional treatment option for symptomatic RN.Despite the absence of Level 1 evidence, these Delphi-survey-formulated recommendations provide actionable guidance for clinical practice. There is a need for prospective randomized trials focusing on symptomatic RN.

Keyword(s): Radionecrosis ; bevacizumab ; corticosteroids ; pseudoprogression

Classification:

Note: #DKTKZFB26# / epub

Contributing Institute(s):
  1. KKE Neuroimmunologie und Hirntumorimmunologie (D170)
  2. DKTK Koordinierungsstelle Frankfurt (FM01)
Research Program(s):
  1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2026
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > D170
Public records
Publications database

 Record created 2026-07-10, last modified 2026-07-11



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)